AACR 2019 – Baylor sets the benchmark for Bellicum
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Ash 2018 – Legend’s mystery CAR raises more questions
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
Ash 2018 preview – blood cancers offer biotech a chance at redemption
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
The first real challenge to multiple myeloma CAR-T therapy
Amgen’s AMG 420 yielded early but spectacular remissions, leaving Boehringer Ingelheim with egg on its face.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.